2020
Big Data in Transplantation Practice-the Devil Is in the Detail-Fontan-associated Liver Disease.
Kim M, Nguyen A, Lo M, Kumar S, Bucuvalas J, Glynn E, Hoffman M, Fischer R, Emamaullee J. Big Data in Transplantation Practice-the Devil Is in the Detail-Fontan-associated Liver Disease. Transplantation 2020, 105: 18-22. PMID: 32639398, DOI: 10.1097/tp.0000000000003308.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overBig DataChildChild, PreschoolData CollectionData MiningDatabases, FactualFemaleFontan ProcedureHeart Defects, CongenitalHumansInfantInfant, NewbornLiver DiseasesLiver TransplantationMaleMiddle AgedRisk AssessmentRisk FactorsTreatment OutcomeYoung AdultConceptsFontan-associated liver diseasePatients post-FontanPost-FontanLiver diseaseSingle-ventricle heart diseaseHeart-liver transplantationProgressive hepatic fibrosisMultiple health systemsConsequences of chronic exposureFontan procedureFontan RegistryNoncardiac complicationsHeart-liverTime of heartFontan hemodynamicsLiver transplantationHepatocellular carcinomaFontanHepatic fibrosisIndividual patientsHeart diseasePatientsHealth systemAffected childrenTransplantationLong-Term Financial, Psychosocial, and Overall Health-Related Quality of Life After Living Liver Donation
Raza M, Kim M, Ding L, Fong T, Romero C, Genyk Y, Sher L, Emamaullee J. Long-Term Financial, Psychosocial, and Overall Health-Related Quality of Life After Living Liver Donation. Journal Of Surgical Research 2020, 253: 41-52. PMID: 32320896, PMCID: PMC8351216, DOI: 10.1016/j.jss.2020.03.025.Peer-Reviewed Original ResearchConceptsHealth-related quality of lifeHealth-related qualityQuality of lifeHRQoL outcomesU.S. population normsShort Form-36Quality of Life SurveyFollow-upDiverse patient populationsPhysical activityHealthy potential donorsPopulation normsLiving liver donorsShort formHealth insuranceLifetime follow-upU.S. populationQuality of Life Survey dataLife SurveyAging populationLiver donationPatient populationPostdonation follow-upOutcomesWork performance
2008
Myogenic Akt signaling upregulates the utrophin–glycoprotein complex and promotes sarcolemma stability in muscular dystrophy
Peter A, Ko C, Kim M, Hsu N, Ouchi N, Rhie S, Izumiya Y, Zeng L, Walsh K, Crosbie R. Myogenic Akt signaling upregulates the utrophin–glycoprotein complex and promotes sarcolemma stability in muscular dystrophy. Human Molecular Genetics 2008, 18: 318-327. PMID: 18986978, PMCID: PMC2638781, DOI: 10.1093/hmg/ddn358.Peer-Reviewed Original ResearchConceptsMuscle wastingMuscular dystrophyAkt signalingExpression of utrophinProgressive muscle wastingDuchenne muscular dystrophyModulation of AktFunction of dystrophinSarcolemma stabilityPhysiological compensatory mechanismsDystrophin mutationsMouse modelSarcolemma damageDisease outcomeIncreased AktSarcolemma membraneDystrophyCompensatory mechanismsSignaling pathwayDystrophinSarcolemmaUtrophin-glycoprotein complexAkt
2006
Association of increased interferon‐inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus
Feng X, Wu H, Grossman J, Hanvivadhanakul P, FitzGerald J, Park G, Dong X, Chen W, Kim M, Weng H, Furst D, Gorn A, McMahon M, Taylor M, Brahn E, Hahn B, Tsao B. Association of increased interferon‐inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis & Rheumatism 2006, 54: 2951-2962. PMID: 16947629, DOI: 10.1002/art.22044.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosus patientsSystemic lupus erythematosusActive renal diseaseLupus nephritis patientsIFN scoreDisease activityLupus erythematosusNephritis patientsLupus nephritisPresence of anti-double-stranded DNARenal diseaseNormal controlsPhysician Global Assessment scoreAnti-dsDNA antibody positivityAnti-double-stranded DNAHigher IFN scoresInactive lupus nephritisSafety of EstrogensGlobal Assessment scoreAssociated with neurological manifestationsAssociated with proteinuriaLupus nephritis therapyPeripheral blood cellsRheumatic disease controlsExpression levels